Table 4 Cost–utility when age limit is raised to 60 and 70 years (representing an annual cohort from England)
Scenario | Base case (CRC under 50 years) | CRC under 60 years | CRC under 70 years |
|---|---|---|---|
Incremental costs of Strategy 5 vs Strategy 1(1) [£ Thousands] | |||
Diagnosis | 586.0 | 1590.5 | 4132.2 |
CRC prevention | 817.1 | 1630.3 | 2990.5 |
CRC treatment | −725.2 | −1450.7 | −2604.6 |
EC prevention | 374.5 | 772.5 | 1430.4 |
EC treatment | −68.0 | −139.2 | −247.9 |
Total | 984.5 | 2403.4 | 5700.5 |
Incremental QALYs Strategy 5 vs Strategy 1(1) | |||
Short-term | −4.6 | −9.5 | −18.1 |
Long-term | 183.9 | 322.4 | 574.4 |
Total | 179.3 | 312.9 | 556.3 |
Cost–utility of Strategy 5 vs Strategy 1(1) | |||
ICER [cost per QALY gained] | £5491 | £7681 | £10247 |
INHB at WTP £20,000/QALY [QALYs] | 130.1 | 192.8 | 271.3 |